Mesoblast sees little impact from proposed Valeant/Cephalon deal
This article was originally published in Scrip
Executive Summary
The Australian regenerative medicine venture Mesoblast expects to weather virtually unscathed the attempt by Valeant Pharmaceuticals to acquire some or all of the assets of Mesoblast's alliance partner, the US speciality pharma firm Cephalon, saying it is protected by plenty of cash on hand and existing agreements.